UroGen Pharma (URGN) Tops Q3 EPS by 27c

UroGen Pharma (NASDAQ: URGN) reported Q3 EPS of ($0.55), $0.27 better than the analyst estimate of ($0.82). Revenue for the quarter came in at $25.2 million versus the consensus estimate of $24.2 million.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• CalPrivate Bank names Andra Frazier as chief credit officer